NZ592238A - Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives - Google Patents
Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivativesInfo
- Publication number
- NZ592238A NZ592238A NZ592238A NZ59223809A NZ592238A NZ 592238 A NZ592238 A NZ 592238A NZ 592238 A NZ592238 A NZ 592238A NZ 59223809 A NZ59223809 A NZ 59223809A NZ 592238 A NZ592238 A NZ 592238A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- imidazo
- tetrahydro
- isopropyl
- pyridine
- Prior art date
Links
- OJQDVKRXYOZHRR-UHFFFAOYSA-N 4-propan-2-yl-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine Chemical class CC(C)C1NCCC2=C1N=CN2 OJQDVKRXYOZHRR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- WEEUMIAFJMZQBT-UHFFFAOYSA-N (2-chloro-2,2-difluoroethyl) 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound CC(C)C1N(C(=O)OCC(F)(F)Cl)CCC2=C1N=CN2 WEEUMIAFJMZQBT-UHFFFAOYSA-N 0.000 abstract 1
- BZLMDWBBPQZXJD-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)methyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC=1C=C(C)ON=1 BZLMDWBBPQZXJD-UHFFFAOYSA-N 0.000 abstract 1
- PJBJKGROWVXEJW-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound CC(C)C1N(C(=O)OCC(Cl)(Cl)Cl)CCC2=C1N=CN2 PJBJKGROWVXEJW-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- -1 NR4AR4B-alkyl Chemical group 0.000 abstract 1
- AMIPLQUGEQTRSM-GWCFXTLKSA-N [(3s)-oxolan-3-yl] (4s)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound N1([C@H](C=2N=CNC=2CC1)C(C)C)C(=O)O[C@H]1CCOC1 AMIPLQUGEQTRSM-GWCFXTLKSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- XDPADPUVPMVMEV-HOCLYGCPSA-N benzyl (4s,6s)-6-carbamoyl-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound N1([C@H](C=2N=CNC=2C[C@H]1C(N)=O)C(C)C)C(=O)OCC1=CC=CC=C1 XDPADPUVPMVMEV-HOCLYGCPSA-N 0.000 abstract 1
- WDCFTEMOHNOANY-UHFFFAOYSA-N benzyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=CC=C1 WDCFTEMOHNOANY-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- HPOQKUXMZZNIDG-UHFFFAOYSA-N pyridin-2-ylmethyl 4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound C1CC=2NC=NC=2C(C(C)C)N1C(=O)OCC1=CC=CC=N1 HPOQKUXMZZNIDG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0801979 | 2008-09-16 | ||
| US10673408P | 2008-10-20 | 2008-10-20 | |
| PCT/EP2009/062011 WO2010031789A1 (en) | 2008-09-16 | 2009-09-16 | New compounds i |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592238A true NZ592238A (en) | 2012-11-30 |
Family
ID=41226693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592238A NZ592238A (en) | 2008-09-16 | 2009-09-16 | Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8263616B2 (enExample) |
| EP (1) | EP2334672B1 (enExample) |
| JP (1) | JP5539989B2 (enExample) |
| CN (1) | CN102232073B (enExample) |
| AU (1) | AU2009294660B2 (enExample) |
| BR (1) | BRPI0918602B8 (enExample) |
| CA (1) | CA2737527C (enExample) |
| DK (1) | DK2334672T3 (enExample) |
| EA (1) | EA019167B1 (enExample) |
| ES (1) | ES2440279T3 (enExample) |
| MX (1) | MX2011002581A (enExample) |
| NZ (1) | NZ592238A (enExample) |
| PL (1) | PL2334672T3 (enExample) |
| PT (1) | PT2334672E (enExample) |
| WO (1) | WO2010031789A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2334672T3 (da) | 2008-09-16 | 2013-12-02 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinforbindelser som inhibitorer af SSAO |
| UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| CN102311396B (zh) * | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| CN103889983B (zh) | 2011-09-14 | 2015-12-09 | 普罗克西梅根有限公司 | 酶抑制剂化合物 |
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| GB201416444D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201416446D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| KR102041761B1 (ko) | 2015-03-02 | 2019-11-06 | 닛본 덴끼 가부시끼가이샤 | 디코딩 장치, 수신기기, 송신기기, 송수신 시스템, 디코딩 방법, 및 디코딩 프로그램이 저장된 저장매체 |
| GB201507048D0 (en) | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
| GB201507031D0 (en) | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| GB201513115D0 (en) | 2015-07-24 | 2015-09-09 | Proximagen Ltd | New therapeutic compound and use in therapy |
| IL300788A (en) | 2015-11-20 | 2023-04-01 | Forma Therapeutics Inc | Furinones as ubiquitin-specific protease 1 inhibitors |
| JP2019502672A (ja) * | 2015-12-07 | 2019-01-31 | ベネボレンタイ ケンブリッジ リミティド | 疼痛の治療のためのｖａｐ−１阻害剤 |
| GB201618029D0 (en) * | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
| EP3902802A4 (en) * | 2018-12-28 | 2022-09-07 | Forma Therapeutics, Inc. | COMPOSITIONS FOR INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5285191A (en) * | 1976-01-07 | 1977-07-15 | Farmaceutici Italia | Novel 4*5*6*77tetrahydroimidazoo *4*55c*pyridine derivative process for preparing same and medicine having antiiulcer antiisecretion and antiicolline activities containing same |
| US4141899A (en) * | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
| IT1098015B (it) * | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| SE0004101D0 (sv) * | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
| AU2002214505A1 (en) * | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| US6576249B1 (en) * | 2000-11-13 | 2003-06-10 | El Gendler | Bone putty and method |
| DK2334672T3 (da) | 2008-09-16 | 2013-12-02 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinforbindelser som inhibitorer af SSAO |
-
2009
- 2009-09-16 DK DK09783085.5T patent/DK2334672T3/da active
- 2009-09-16 JP JP2011526516A patent/JP5539989B2/ja not_active Expired - Fee Related
- 2009-09-16 WO PCT/EP2009/062011 patent/WO2010031789A1/en not_active Ceased
- 2009-09-16 US US13/062,318 patent/US8263616B2/en not_active Expired - Fee Related
- 2009-09-16 CA CA2737527A patent/CA2737527C/en not_active Expired - Fee Related
- 2009-09-16 AU AU2009294660A patent/AU2009294660B2/en not_active Ceased
- 2009-09-16 CN CN200980136970.1A patent/CN102232073B/zh not_active Expired - Fee Related
- 2009-09-16 EA EA201100391A patent/EA019167B1/ru not_active IP Right Cessation
- 2009-09-16 BR BRPI0918602A patent/BRPI0918602B8/pt not_active IP Right Cessation
- 2009-09-16 NZ NZ592238A patent/NZ592238A/xx not_active IP Right Cessation
- 2009-09-16 PT PT97830855T patent/PT2334672E/pt unknown
- 2009-09-16 ES ES09783085.5T patent/ES2440279T3/es active Active
- 2009-09-16 PL PL09783085T patent/PL2334672T3/pl unknown
- 2009-09-16 EP EP09783085.5A patent/EP2334672B1/en not_active Not-in-force
- 2009-09-16 MX MX2011002581A patent/MX2011002581A/es active IP Right Grant
-
2012
- 2012-08-06 US US13/567,146 patent/US8569338B2/en not_active Expired - Fee Related
-
2013
- 2013-10-25 US US14/062,969 patent/US9035066B2/en active Active
-
2015
- 2015-04-13 US US14/684,813 patent/US9493457B2/en not_active Expired - Fee Related
-
2016
- 2016-10-27 US US15/335,751 patent/US9890160B2/en active Active
-
2017
- 2017-12-29 US US15/858,407 patent/US10399973B2/en active Active
-
2019
- 2019-07-17 US US16/514,413 patent/US11040969B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ592238A (en) | Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| EP2613782A4 (en) | INDAZONE DERIVATIVES AS ERK HEMMER | |
| WO2010138652A4 (en) | Methods for treating kaposi sarcoma | |
| RU2013149174A (ru) | Новое имидазооксазиновое соединение или его соль | |
| EA200970655A1 (ru) | 6-замещенные пиримидины, ингибирующие вич | |
| RU2012129168A (ru) | Производные оксазина | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| CA2864222A1 (en) | Cycloalkane derivative | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
| HK1202541A1 (en) | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors | |
| RU2011131048A (ru) | Новое бициклическое гетероциклическое соединение | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| MX348228B (es) | Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. | |
| MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| WO2008125600A3 (en) | Pyrazole derivatives as p2x7 modulators | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
| IL283368B1 (en) | An imidazo[1,2-b]pyridazin-7-yl-urea compound and a medicine comprising the compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2016 BY CPA GLOBAL Effective date: 20130801 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2017 BY COMPUTER PACKAGES INC Effective date: 20160831 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2018 BY CPA GLOBAL Effective date: 20170803 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2019 BY JAMES + WELLS Effective date: 20180906 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2020 BY JAMES + WELLS Effective date: 20190905 |
|
| LAPS | Patent lapsed |